NASOPHARYNGEAL CARCINOMA (NPC)
Clinical trials for NASOPHARYNGEAL CARCINOMA (NPC) explained in plain language.
Never miss a new study
Get alerted when new NASOPHARYNGEAL CARCINOMA (NPC) trials appear
Sign up with your email to follow new studies for NASOPHARYNGEAL CARCINOMA (NPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New risk model may let some NPC patients avoid unnecessary chemo
Disease control Recruiting nowThis study tests a personalized approach for people with advanced nasopharyngeal cancer. After standard chemoradiation, some patients get extra therapy to prevent the cancer from returning. But this extra therapy can cause side effects. The trial uses a new risk model (RAIRI) to …
Matched conditions: NASOPHARYNGEAL CARCINOMA (NPC)
Phase: PHASE3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New combo therapy aims to improve survival in advanced nose cancer
Disease control Recruiting nowThis phase 3 trial tests whether a new drug (Becotatug vedotin) plus immunotherapy (sintilimab) and standard chemoradiation works better than current standard treatment for high-risk nasopharyngeal cancer. About 266 adults with advanced but non-spread cancer will be randomly assi…
Matched conditions: NASOPHARYNGEAL CARCINOMA (NPC)
Phase: PHASE3 • Sponsor: First Affiliated Hospital of Guangxi Medical University • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New immune combo targets hard-to-treat nose and throat cancer
Disease control Recruiting nowThis study tests a combination of two immune-boosting drugs (iparomlimab and tuvonralimab) plus a targeted antibody (nimotuzumab) in people with advanced nasopharyngeal cancer that got worse after standard first treatment. About 41 adults aged 18-70 will receive the therapy to se…
Matched conditions: NASOPHARYNGEAL CARCINOMA (NPC)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Proton beam vs. standard radiation: which is safer for advanced throat cancer?
Disease control Recruiting nowThis study compares two radiation methods—proton therapy and standard photon therapy—for people with advanced nasopharyngeal cancer. All 300 participants will receive chemotherapy and immunotherapy alongside radiation. The goal is to see which approach causes fewer severe side ef…
Matched conditions: NASOPHARYNGEAL CARCINOMA (NPC)
Phase: PHASE3 • Sponsor: Man Hu • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Could less radiation be enough? new trial for advanced throat cancer
Disease control Recruiting nowThis study is for people with advanced nasopharyngeal cancer (a type of throat cancer) whose tumors shrank significantly after initial chemotherapy and immunotherapy. It compares a lower dose of radiation therapy to the standard dose, both given with additional chemo and immunoth…
Matched conditions: NASOPHARYNGEAL CARCINOMA (NPC)
Phase: PHASE3 • Sponsor: Ming-Yuan Chen • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Could less radiation be just as effective for neck cancer?
Disease control Recruiting nowThis study tests whether giving radiation only to the parts of the neck where cancer has spread works as well as treating the entire neck in people with nasopharyngeal carcinoma. About 462 adults with stage I–III disease will be randomly assigned to receive either standard or ind…
Matched conditions: NASOPHARYNGEAL CARCINOMA (NPC)
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Could less radiation be better? new trial aims to reduce side effects for advanced nose cancer patients
Disease control Recruiting nowThis phase 3 trial tests whether giving less radiation to low-risk areas (reduced-target) is as effective as standard full-target radiation for patients with metastatic nasopharyngeal carcinoma who have already responded to chemotherapy and immunotherapy. The study involves 166 a…
Matched conditions: NASOPHARYNGEAL CARCINOMA (NPC)
Phase: PHASE3 • Sponsor: Ming-Yuan Chen • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for recurrent throat cancer: Radiation-Immunotherapy combo shows promise
Disease control Recruiting nowThis phase II trial tests a new approach for recurrent nasopharyngeal carcinoma (a type of throat cancer) that has come back after initial treatment and cannot be removed by surgery. The treatment combines a special radiation schedule (low and high doses) with an immunotherapy dr…
Matched conditions: NASOPHARYNGEAL CARCINOMA (NPC)
Phase: PHASE2 • Sponsor: Jiangxi Provincial Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for Hard-to-Treat nasopharyngeal cancer: targeted drug HLX43 enters phase 2 trial
Disease control Recruiting nowThis phase 2 trial tests HLX43, a drug that targets a protein called PD-L1 on cancer cells and delivers a toxin to kill them. It is for people with recurrent or metastatic nasopharyngeal carcinoma who have failed or cannot tolerate second-line therapy. About 70 participants will …
Matched conditions: NASOPHARYNGEAL CARCINOMA (NPC)
Phase: PHASE2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New inhaler may ease mouth pain for head and neck cancer patients
Symptom relief Recruiting nowThis study tests if a drug called Sapylin, given through an inhaler, can prevent or reduce painful mouth sores caused by chemotherapy and radiation for nasopharyngeal cancer. About 180 adults with advanced cancer will be randomly assigned to receive either Sapylin or the standard…
Matched conditions: NASOPHARYNGEAL CARCINOMA (NPC)
Phase: PHASE3 • Sponsor: Affiliated Hospital of Guangdong Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 09:11 UTC
-
New risk model may personalize Post-Chemo decisions for nasopharyngeal cancer
Knowledge-focused Recruiting nowThis observational study is testing whether a new tool called RAIRI can better identify which patients with nasopharyngeal cancer might benefit from additional therapy after standard chemoradiation. About 900 adults with non-metastatic disease will be followed to see if the RAIRI…
Matched conditions: NASOPHARYNGEAL CARCINOMA (NPC)
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
New scan could help doctors pick the right treatment for nasopharyngeal cancer
Knowledge-focused Recruiting nowThis study tests whether a special PET scan can show how much of a certain protein (SSTR2) is present in nasopharyngeal cancer tumors. Ten adults with EBV-related nasopharyngeal cancer will get the scan before and after starting chemotherapy or chemoradiation. The goal is to see …
Matched conditions: NASOPHARYNGEAL CARCINOMA (NPC)
Phase: PHASE1, PHASE2 • Sponsor: University Medical Center Groningen • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC